

Research Article

A Model for SARS-CoV-2 Infection with Treatment

Amar Nath Chatterjee ¹ and Fahad Al Basir ²

¹Department of Mathematics, K.L.S. College, Nawada, Magadh University, Bodh Gaya, Bihar 805110, India

²Department of Mathematics, Asansol Girls' College, Asansol-4, West Bengal 713304, India

Correspondence should be addressed to Fahad Al Basir; fahadalbasir@yahoo.com

Received 2 April 2020; Revised 6 July 2020; Accepted 22 July 2020; Published 1 September 2020

Academic Editor: Raul Alcaraz

Copyright © 2020 Amar Nath Chatterjee and Fahad Al Basir. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The current emergence of coronavirus (SARS-CoV-2) puts the world in threat. The structural research on the receptor recognition by SARS-CoV-2 has identified the key interactions between SARS-CoV-2 spike protein and its host (epithelial cell) receptor, also known as angiotensin-converting enzyme 2 (ACE2). It controls both the cross-species and human-to-human transmissions of SARS-CoV-2. In view of this, we propose and analyze a mathematical model for investigating the effect of CTL responses over the viral mutation to control the viral infection when a postinfection immunostimulant drug (pidotimod) is administered at regular intervals. Dynamics of the system with and without impulses have been analyzed using the basic reproduction number. This study shows that the proper dosing interval and drug dose both are important to eradicate the viral infection.

1. Introduction

A novel coronavirus named SARS-CoV-2 (an interim name proposed by WHO (World Health Organization)) became a pandemic since December 2019. The first infectious respiratory syndrome was recognized in Wuhan, Hubei province of China. Dedicated virologists identified and recognized the virus within a short time [1]. The SARS-CoV-2 is a single-stranded RNA virus genome which is closely related to severe acute respiratory syndrome- (SARS-) CoV [2]. The infection of SARS-CoV-2 is associated with a SARS-CoV-like a disease with a fatality rate of 3.4% [3]. The World Health Organization (WHO) have named the disease as COVID-19 and declared it as a public health emergency worldwide [4].

The common symptoms of COVID-19 are fever, fatigue, dry cough, and myalgia. Also, some patients suffer from headaches, abdominal pain, diarrhea, nausea, and vomiting. In the acute phase of infection, the disease may lead to respiratory failure which leads to death also. From clinical observation, within 1-2 days after patient symptoms, the patient becomes morbid after 4-6 days and the infection

may clear within 18 days [5] depending on the immune system. Thus, appropriate quarantine measure for a minimum of two weeks is taken by the public health authorities for inhibiting community spread [6].

In [1], Zhou et al. identified the respiratory tract as the principal infection site for COVID-19 infection. SARS-CoV-2 infects primary human airway epithelial cells. The angiotensin-converting enzyme 2 (ACE2) receptor of epithelial cells plays an important role in cellular entry [1, 7]. It has been observed that ACE2 could be expressed in the oral cavity. ACE2 receptors are higher in the tongue than buccal and gingival tissues. These findings imply that the mucosa of the oral cavity may be a potentially high-risk route of COVID-19 infection. Thus, epithelial cells of the tongue are the major routes of entry for COVID-19. Zhou et al. [1] also reported that SARS-CoV-2 spikes (S) bind with the ACE2 receptor of epithelial cells with high affinity. The bonding between S (spikes) of SARS-CoV-2 and ACE2 [7] results from the fusion between the viral envelope and the target cell membrane, and the epithelial cells become infected. The S protein plays a major role in the induction of protective immunity during the infection of SARS-CoV-

2 by eliciting neutralization antibody and T cell responses [8]. The S protein is not only capable of neutralizing antibody, but it also contains several immunogenic T cell epitopes. Some of the epitopes are found in either the S1 or S2 domain. These proteins are useful for SARS-CoV-2 drug development [9].

We know that virus clearance after acute infection is associated with strong antibody responses. Antibody responses have the potential to control the infection [10]. Also, CTL responses help to resolve infection and virus persistence caused by weak CTL responses [11]. Antibody responses against SARS-CoV-2 play an important role in preventing the viral entry process [8]. Hsueh et al. [2] found that antibodies block viral entry by binding to the S glycoprotein of SARS-CoV-2. To fight against the pathogen SARS-CoV-2, the body requires SARS-CoV-2-specific CD4⁺ T helper cells for developing this specific antibody [8]. Antibody-mediated immunity protection helps the anti-SARS-CoV serum to neutralize COVID-19 infection. Besides that, the role of T cell responses in COVID-19 infection is very much important. Cytotoxic T lymphocyte (CTL) responses are important for recognizing and killing infected cells, particularly in the lungs [8]. But the kinetics of the CTL responses and antibody responses during SARS-CoV-2 infection is yet to be explored. Our study will focus on the role of CTL and its possible implication on treatment and drug development. The drug that stimulates the CTL responses represents the best hope for control of COVID-19. Here, we have modeled the situation where CTLs can effectively control the viral infection when the postinfection drug is administered at regular intervals.

Mathematical modeling with real data can help in predicting the dynamics and control of an infectious disease [12, 13]. A four-dimensional dynamical model for a viral infection is proposed by Tang et al. [14] for MERS-CoV mediated by DPP4 receptors. In the case of SARS-CoV-2, the infection process is almost similar with MERS-CoV and SARS-CoV. For SARS-CoV-2 infection, the ACE2 receptors of epithelial cells are the major target area.

Since the dynamics of the disease transmission of SARS-CoV-2 in the cellular level is yet to be explored, we investigate the system in the light of the previous literature of [14–18] to formulate the dynamic model which plays a significant role in describing the interaction between uninfected cells, free virus, and CTL responses. We propose a novel deterministic model which describes the cell biological infection of SARS-CoV-2 with epithelial cells and the role of the ACE2 receptor.

We explained the dynamics in the acute infection stage. It has been observed that CTLs proliferate and differentiate antibody production after they encounter antigens. Here, we investigate the effect of CTL responses over the viral mutation to control viral infection when a postinfection drug is administered at regular intervals by a mathematical perspective.

It is clinically evident that immunostimulants play a crucial role in the case of respiratory disease. Among the currently available immunostimulants, pidotimod is the most effective for the respiratory disease [19]. Pidotimod increases the level

of immunoglobulins (IgA, IgM, and IgG) and activates the CTL responses to fight against the disease.

In this article, we have considered the infection dynamics of SARS-CoV-2 infection in the acute stage. We have used impulsive differential equations to study the immunostimulant drug dynamics and the effects of perfect drug adherence. In recent years, the effects of perfect adherence have been studied by using impulsive differential equations in [20–26]. With the help of impulsive differential equations, the effect of maximal acceptable drug holidays and optimal dosage can be found more precisely [20, 26].

The article is organized as follows. The very next section contains the formulation of the impulsive mathematical model. Dynamics of the system without impulses has been provided in Section 3. The system with impulses has been analyzed in Section 4. Numerical simulations, on the basis of the outcomes of Sections 3 and 4, have been included in Section 5. Discussion in Section 6 concludes the paper.

2. Model Formulation

As discussed in the previous section, we propose a model considering the interaction between epithelial cells and SARS-CoV-2 virus along with lytic CTL responses over the infected cells. We consider five populations, namely, the uninfected epithelial cells $T(t)$, infected cells $I(t)$, ACE2 receptor of the epithelial cells $E(t)$, SARS-CoV-2 virus $V(t)$ and CTLs against the pathogen $C(t)$.

In this model, we consider which represents the concentration of ACE2 on the surface of uninfected cells, which can be recognized by the surface spike (S) protein of SARS-CoV-2 [27].

It is assumed that the susceptible cells are produced at a rate λ_1 from the precursor cells and die at a rate d_T . The susceptible cells become infected at a rate $\beta E(t)V(t)T(t)$. The constant d_I is the death rate of the infected cells. Infected cells are also cleared by the body's defensive CTLs at a rate p .

The infected cells produce new viruses at the rate md_I during their life, and d_V is the death rate of new virions, where m is any positive integer. It is also assumed that ACE2 is produced from the surface of uninfected cells at the constant rate λ_2 and the ACE2 is destroyed, when free viruses try to infect uninfected cells, at the rate $\theta\beta E(t)V(t)T(t)$ and is hydrolyzed at the rate $d_E E$.

CTL proliferation in the presence of infected cells is described by the term

$$\alpha IC \left(1 - \frac{C}{C_{\max}} \right), \quad (1)$$

which shows the antigen-dependent proliferation. Here, we consider the logistic growth of CTL with C_{\max} as the maximum concentration of CTL, and d_c is its rate of decay.

With the above assumptions, we have the following mathematical model characterizing the SARS-CoV-2 dynamics:

$$\begin{aligned}
\frac{dT}{dt} &= \lambda_1 - \beta EVT - d_T T, \\
\frac{dI}{dt} &= \beta EVT - d_I I - pIC, \\
\frac{dV}{dt} &= md_I I - d_V V, \\
\frac{dE}{dt} &= \lambda_2 - \theta \beta EVT - d_E E, \\
\frac{dC}{dt} &= \alpha IC \left(1 - \frac{C}{C_{\max}}\right) - d_c C.
\end{aligned} \tag{2}$$

A short description of the model parameters and their values is shown in Table 1. We now modify the above model by incorporating pulse periodic drug dosing using impulsive differential equations [28, 29].

We consider the perfect adherence behavior of the immunostimulant drug for SARS-CoV-2-infected patients at fixed drug dosing times $t_k, k \in \mathbb{N}$.

We assume that CTL cells increase by a fixed amount ω , which is proportional to the total number of CTLs that the drug can stimulate. Thus, the above model takes the following form:

$$\begin{aligned}
\frac{dT}{dt} &= \lambda_1 - \beta EVT - d_T T, \\
\frac{dI}{dt} &= \beta EVT - d_I I - pIC, \\
\frac{dV}{dt} &= md_I I - d_V V, \\
\frac{dE}{dt} &= \lambda_2 - \theta \beta EVT - d_E E, \\
\frac{dC}{dt} &= \alpha IC \left(1 - \frac{C}{C_{\max}}\right) - d_c C, \quad t \neq t_k, \\
C(t_k^+) &= \omega + C(t_k^-), \quad t = t_k.
\end{aligned} \tag{3}$$

Here, $C(t_k^-)$ denotes the CTL cell concentration immediately before the impulse, $C(t_k^+)$ denotes the concentration after the impulse, and ω is the fixed amount which is proportional to the total number of CTLs the drug stimulates at each impulse time $t_k, k \in \mathbb{N}$.

Remark 1. It can be noted that when there is no drug application in the system, model (3) becomes model (2).

3. Analysis of the System without the Drug

In this section, we analyze the dynamics of the system without impulses, i.e., system (1). We have derived the basic reproduction number for the system. Stability of equilibria is discussed using the number.

3.1. Existence of Equilibria. Model (2) has three steady states, namely, (i) the disease-free equilibrium $E_1(\lambda_1/d_T, 0, 0, \lambda_2/d_E,$

TABLE 1: Set of parameter values used of numerical simulations.

Parameter	Explanation	Assigned value
λ_1	Production rate of uninfected cell	5
λ_2	Production rate of ACE2	1
β	Disease transmission rate	0.0001
θ	Bonding rate of ACE2	0.3
d_T	Death rate of uninfected cells	0.1
d_I	Death rate of infected cells	0.1
d_V	Removal rate of virus	0.1
d_E	Hydrolyzing rate of epithelial cells	0.1
d_c	Decay rate of CTL	0.1
p	Killing rate of infected cells by CTL	0.01
m	Number of new virions produced	10-100
α	Proliferation rate of CTL	0.22
C_{\max}	Maximum proliferation of CTL	100

0); (ii) with $\bar{E} > d_T d_V / \beta \lambda_1 m$, there is a CTL response-free equilibrium, $E_2(\bar{T}, \bar{I}, \bar{V}, \bar{E}, 0)$, where

$$\begin{aligned}
\bar{T} &= \frac{d_V}{\beta m \bar{E}}, \\
\bar{I} &= \frac{\beta \lambda_1 m \bar{E} - d_T d_V}{\beta d_I m \bar{E}}, \\
\bar{V} &= \frac{\beta \lambda_1 m \bar{E} - d_T d_V}{\beta d_V \bar{E}}, \\
\bar{E} &= \frac{-(\theta \beta \lambda_1 m - \beta \lambda_2 m) + \sqrt{(\theta \beta \lambda_1 m - \beta \lambda_2 m)^2 + 4 \beta m d_T d_V d_E \theta}}{2 \beta d_E m};
\end{aligned} \tag{4}$$

and (iii) the endemic equilibrium E^* which is given by

$$\begin{aligned}
T^* &= \frac{\lambda_1 \alpha - d_I \alpha I^* - p d_c}{d_T \alpha}, \\
V^* &= \frac{d_I m I^*}{d_V}, \\
E^* &= \frac{\lambda_2 \alpha - \theta \alpha d_I I^* - \theta p d_c}{d_E \alpha},
\end{aligned} \tag{5}$$

$$C^* = \frac{(\alpha I^* - d_c) C_{\max}}{\alpha I^*}, \tag{6}$$

where I^* is the positive root of the cubic equation

$$L_0 I^3 + L_1 I^2 + L_2 I + L_3 = 0, \tag{7}$$

with

$$\begin{aligned}
L_0 &= -\alpha^2 \theta \beta d_1^3 m, \\
L_1 &= -2\alpha \theta \beta d_1^2 d_c m p + \alpha^2 \theta \beta d_1^2 \lambda_1 m + \alpha^2 \beta d_1^2 \lambda_2 m, \\
L_2 &= \alpha^2 d_T d_1 d_V d_E + \alpha \theta \beta d_1 d_c \lambda_1 m p + \alpha \beta d_1 d_c \lambda_2 m p \\
&\quad - \alpha^2 \beta d_1 \lambda_1 \lambda_2 m - \theta \beta d_1 d_c^2 m p^2, \\
L_3 &= \alpha d_T d_V d_E d_c p.
\end{aligned} \tag{8}$$

Remark 2. Note that $L_0 < 0$ and $L_3 > 0$. Thus, equation (7) has at least one positive real root. If $L_1 > 0$ and $L_2 < 0$, then (3) can have two positive roots. For a feasible endemic equilibrium, we also need

$$\min \left\{ \frac{\lambda_1 \alpha - p d_c}{d_1 \alpha}, \frac{\lambda_2 \alpha - \theta p d_c}{\theta \alpha d_1} \right\} > I^* > \frac{d_c}{\alpha}. \tag{9}$$

3.2. Stability of Equilibria. In this section, the characteristic equation at any equilibrium is determined for the local stability of system (2). Linearizing system (2) at any equilibrium $E(T, I, V, E, C)$ yields the characteristic equation

$$\Delta(\xi) = |\xi I_n - \mathbf{A}| = 0, \tag{10}$$

where I_n is the identity matrix and $\mathbf{A} = [a_{ij}]$ is the following 5×5 matrix given by

$$\mathbf{A} = \begin{bmatrix} -\beta EV - d_T & 0 & -\beta ET & -\beta VT & 0 \\ \beta EV & -d_I - pC & \beta ET & \beta VT & -pI \\ 0 & d_1 m & -d_V & 0 & 0 \\ -\theta \beta EV & 0 & -\theta \beta ET & -\theta \beta VT - d_E & 0 \\ 0 & \alpha C \left(1 - \frac{C}{C_{\max}}\right) & 0 & 0 & a_{55} \end{bmatrix}, \tag{11}$$

with $a_{55} = \alpha I (1 - 2C/C_{\max}) - d_c$. We finally get the characteristic equation as

$$\psi(\xi) = \xi^5 + A_1 \xi^4 + A_2 \xi^3 + A_3 \xi^2 + A_4 \xi + A_5 = 0. \tag{12}$$

The coefficients A_i , $i = 1, 2, \dots, 5$, are given in the appendix.

Looking at stability of any equilibrium E , the Routh-Hurwitz criterion gives that all roots of this characteristic

equation (12) have negative real parts, provided the following conditions hold

$$\begin{aligned}
A_5 &> 0, \\
A_1 A_2 - A_3 &> 0, \\
A_3 (A_1 A_2 - A_3) - A_1 (A_1 A_4 - A_5) &> 0, \\
(A_1 A_2 - A_3)(A_3 A_4 - A_2 A_5) - (A_1 A_4 - A_5)^2 &> 0.
\end{aligned} \tag{13}$$

Let us define the basic reproduction number as

$$R_0 = \frac{m \beta \lambda_1 \lambda_2}{d_T d_E d_V}. \tag{14}$$

Then, using (5), we can derived the following result.

Theorem 3. *Disease-free equilibrium $E_1(\lambda_1/d_T, 0, 0, \lambda_2/d_E, 0)$ of model (2) is stable for $R_0 < 1$ and unstable for $R_0 > 1$.*

At E_2 , one eigenvalue is $-d_c$ and the rest of the eigenvalues satisfy the following equation:

$$\xi^4 + B_1 \xi^3 + B_2 \xi^2 + B_3 \xi + B_4 = 0. \tag{15}$$

The coefficients B_i , $i = 1, 2, \dots, 5$, are given in the appendix.

Using the Routh-Hurwitz criterion, we have the following theorem:

Theorem 4. *The CTL-free equilibrium, $E_2(\bar{T}, \bar{I}, \bar{V}, \bar{E}, 0)$, is asymptotically stable if and only if the following conditions are satisfied:*

$$\begin{aligned}
B_1 &> 0, \\
B_2 &> 0, \\
B_3 &> 0, \\
B_4 &> 0, \\
B_1 B_2 - B_3 &> 0, \\
(B_1 B_2 - B_3) B_3 - B_1^2 B_4 &> 0.
\end{aligned} \tag{16}$$

Denoting $A_i^* = A_i(E^*)$ and using (5), we have the following theorem establishing the stability of coexisting equilibrium E^* .

Theorem 5. *The coexisting equilibrium E^* is asymptotically stable if and only if the following conditions are satisfied:*

$$\begin{aligned}
A_5^* &> 0, \\
A_1^* A_2^* - A_3^* &> 0, \\
A_3^* (A_1^* A_2^* - A_3^*) - A_1^* (A_1^* A_4^* - A_5^*) &> 0, \\
(A_1^* A_2^* - A_3^*) (A_3^* A_4^* - A_2^* A_5^*) - (A_1^* A_4^* - A_5^*)^2 &> 0.
\end{aligned} \tag{17}$$

4. Dynamics of the System with Impulsive Drug Dosing

In this section, we consider the model system (3). Before analyzing the system, we first discuss the one-dimensional impulse system as follows:

$$\begin{aligned} \frac{dC}{dt} &= \alpha IC \left(1 - \frac{C}{C_{\max}}\right) - d_c C, \quad t \neq t_k, \\ C(t_k^+) &= \omega + C(t_k^-), \quad t = t_k. \end{aligned} \quad (18)$$

$C(t_k^-)$ denotes the CTL responses immediately before the impulse drug dosing, $C(t_k^+)$ denotes the concentration after the impulse, and ω is the dose that is taken at each impulse time t_k , $k \in \mathbb{N}$.

We now consider the following linear system:

$$\begin{aligned} \frac{dC}{dt} &= -d_c C, \quad t \neq t_k, \\ \Delta C &= \omega, \quad t = t_k, \end{aligned} \quad (19)$$

where $\Delta = C(t_k^+) - C(t_k^-)$. Let $\tau = t_{k+1} - t_k$ be the period of the campaign. The solution of system (10) is

$$C(t) = C(t_k^+) e^{-d_c(t-t_k)}, \quad \text{for } t_k < t \leq t_{k+1}. \quad (20)$$

In presence of impulsive dosing, we can get the recursion relation at the moments of impulse as

$$C(t_k^+) = C(t_k^-) + \omega. \quad (21)$$

Thus, the amount of CTL before and after the impulse is obtained as

$$\begin{aligned} C(t_k^+) &= \frac{\omega(1 - e^{-k\tau d_c})}{1 - e^{-\tau d_c}}, \\ C(t_{k+1}^-) &= \frac{\omega(1 - e^{-k\tau d_c})e^{-\tau d_c}}{1 - e^{-\tau d_c}}. \end{aligned} \quad (22)$$

Thus, the limiting case of the CTL amount before and after one cycle is as follows:

$$\begin{aligned} \lim_{k \rightarrow \infty} C(t_k^+) &= \frac{\omega}{1 - e^{-\tau d_c}}, \\ \lim_{k \rightarrow \infty} C(t_{k+1}^-) &= \frac{\omega e^{-\tau d_c}}{1 - e^{-\tau d_c}}, \\ C(t_{k+1}^+) &= \frac{\omega e^{-\tau d_c}}{1 - e^{-\tau d_c}} + \omega = \frac{\omega}{1 - e^{-\tau d_c}}. \end{aligned} \quad (23)$$

Definition 6. Let $\Lambda \equiv (S_u, S_a, I, C)$ and $B_0 = [B : R_+^4 \rightarrow R_+]$; then, we say that B belong to class B_0 if the following conditions hold:

- (i) B is continuous on $(t_k, t_{k+1}] \times R_+^3$, $n \in \mathbb{N}$, and for all $\Lambda \in R^4$, $\lim_{(t, \mu) \rightarrow (t_k^+, \Lambda)} B(t, \mu) = B(t_k^+, \Lambda)$ exists

- (ii) B is locally Lipschitzian in Λ

We now recall some results for our analysis from [28, 29].

Lemma 7. Let $Z(t)$ be a solution of system (9) with $Z(0^+) \geq 0$. Then, $Z_i(t) \geq 0$, $i = 1, \dots, 4$, for all $t \geq 0$. Moreover, $Z_i(t) > 0$, $i = 1, \dots, 4$, for all $t > 0$ if $Z_i(0^+) > 0$, $i = 1, \dots, 4$.

Lemma 8. There exists a constant γ such that $T(t) \leq \gamma$, $I(t) \leq \gamma$, $V(t) \leq \gamma E(t) \leq \gamma$, and $C(t) \leq \gamma$ for each and every solution $Z(t)$ of system (9) for all sufficiently large t .

Lemma 9. Let $B \in B_0$ and also consider that

$$\begin{aligned} D^+ B(t, Z) &\leq j(t, B(t, Z(t))), \quad t \neq t_k, \\ B(t, Z(t^+)) &\leq \Phi_n(B(t, Z(t))), \quad t = t_k, \end{aligned} \quad (24)$$

where $j : R_+ \times R_+ \rightarrow R$ is continuous in $(t_k, t_{k+1}]$ for $e \in R_+^2$, $n \in \mathbb{N}$, the limit $\lim_{(t, V) \rightarrow (t_k^+, j)} j(t, g) = j(t_k^+, x)$ exists, and Φ_n^i ($i = 1, 2$): $R_+ \rightarrow R_+$ is nondecreasing. Let $y(t)$ be a maximal solution of the following impulsive differential equation:

$$\begin{aligned} \frac{dx(t)}{dt} &= j(t, x(t)), \quad t \neq t_k, \\ x(t^+) &= \Phi_n(x(t)), \quad t = t_k, x(0^+) = x_0, \end{aligned} \quad (25)$$

existing on $(0^+, \infty)$. Then, $B(0^+, Z_0) \leq x_0$ implies that $B(t, Z(t)) \leq y(t)$, $t \geq 0$, for any solution $Z(t)$ of system (9). If j satisfies additional smoothness conditions to ensure the existence and uniqueness of solutions for (12), then $y(t)$ is the unique solution of (12).

We now consider the following subsystem:

$$\frac{dC(t)}{dt} = -d_c C, \quad t \neq t_k, C(t_k^+) = C(t_k) + \omega, C(0^+) = C_0. \quad (26)$$

The lemma provided above gives the following result.

Lemma 10. System (13) has a unique positive periodic solution $\tilde{C}(t)$ with period τ and given by

$$\begin{aligned} \tilde{C}(t) &= \frac{\omega \exp(-d_c(t-t_k))}{1 - \exp(-\tau d_c)}, \quad t_k < t \leq t_{k+1}, \tilde{C}(0^+) \\ &= \frac{d_c}{1 - \exp(-\tau d_c)}. \end{aligned} \quad (27)$$

We use this result to derive the following theorem.

Theorem 11. The disease-free periodic orbit $(\tilde{T}, 0, 0, \tilde{E}, \tilde{C})$ of system (2) is locally asymptotically stable if

$$\tilde{R}_0 < 1, \quad (28)$$




FIGURE 1: Existence and stability of equilibria is shown with respect to R_0 . Parameter values used in this figure are taken from Table 1 and $m = 10$. We have varied the value of β in (0.00001, 0.0001).

where

$$\tilde{R}_0 = \frac{m d_I \beta}{d_T d_E d_V \tau} \int_0^\tau \frac{\tilde{T} \tilde{E}}{d_I + p \tilde{C}} dt. \quad (29)$$

Proof. Let the solution of system (9) without infected people be denoted by $(\tilde{T}, 0, 0, \tilde{E}, \tilde{C})$, where

$$\tilde{C}(t) = \frac{\omega \exp(-d_c(t - t_k))}{1 - \exp(-\tau d_c)}, \quad t_k < t \leq t_{k+1}, \quad (30)$$

with initial condition $C(0^+)$ as in Lemma 10. We now test the stability of the equilibria. The variational matrix at $(\tilde{T}, 0, 0, \tilde{E}, \tilde{C})$ is given by

$$M(t) = [m_{ij}] = \begin{pmatrix} -d_T & 0 & m_{13} & 0 & 0 \\ 0 & -(d_I + p\tilde{C}) & \beta \tilde{E} \tilde{T} & 0 & 0 \\ 0 & m d_I & -d_V & 0 & 0 \\ 0 & 0 & m_{43} & -d_E & 0 \\ 0 & m_{52} & 0 & 0 & -d_c \end{pmatrix}. \quad (31)$$

The monodromy matrix \mathbb{P} of the variational matrix $M(t)$ is

$$\mathbb{P}(\tau) = I_n \exp\left(\int_0^\tau M(t) dt\right), \quad (32)$$

where I_n is the identity matrix. Note that m_{13} , m_{43} , and m_{52} are not required for this analysis; therefore, we have not mentioned their expressions.

We can write $\mathbb{P}(\tau) = \text{diag}(\sigma_1, \sigma_2, \sigma_3, \sigma_4, \sigma_5)$, where σ_i , $i = 1, 2, 3, 4, 5$, are the Floquet multipliers and they are determined as

$$\begin{aligned} \sigma_1 &= \exp(-d_T \tau), \\ \sigma_{2,3} &= \exp\left(\int_0^\tau \frac{1}{2} \left[-A \pm \sqrt{A^2 - 4B}\right] dt\right), \\ \sigma_4 &= \exp(-d_E \tau), \\ \sigma_5 &= \exp(-d_c \tau). \end{aligned} \quad (33)$$

Here, $A = d_I + d_V + p\tilde{C}$ and $B = d_V(d_I + p\tilde{C}) - m d_I \beta \tilde{E} \tilde{T}$. Clearly, $\lambda_{1,4,5} < 1$. It is easy to check that $A^2 - 4B > 0$, and if $B \geq 0$ and hold, then we have $\lambda_{2,3} < 1$. Thus, according to Floquet theory, the periodic solution $(\tilde{T}, 0, 0, \tilde{E}, \tilde{C})$ of system (9) is locally asymptotically stable if the conditions given in (14) hold.

5. Numerical Results and Discussion

In this section, we have observed the dynamical behaviors of the system without the drug (Figures 1 and 2) and with impulsive effect of the drug dose (Figures 3 and 4) through numerical simulations taking the parameters mainly from [14, 19, 30].

We have mainly focused on the role of CTL and its possible implication on the treatment and drug development. The drug that stimulates the CTL responses represents the best hope for control of COVID-19. Here, we have determined the situation where CTLs can effectively control the viral infection when the postinfection drug is administered at regular intervals.

Existence of equilibria of the system without the drug dose is shown for different values of basic reproduction number R_0 . In plotting Figure 1, we have varied the value of infection rate β . It is observed that for the lower infection rate (that corresponds to $R_0 < 1$), disease-free equilibrium E_1 is stable (corroborated with Theorem 3). It becomes unstable and ensures the existence of the CTL-free equilibrium E_2 which




FIGURE 2: In the absence of the drug, the effect of the growth rate of CTL, i.e., α on the steady-state values of model population, is shown. Parameter values used in this figure are the same as Figure 1 except α .

is stable if $R_0 < 2.957$ (which corresponds to $\beta = 0.00005963$) and unstable otherwise. (This satisfies Theorem 4.) Again, we see that when E_2 is unstable, E^* is feasible. Also, whenever E^* exists, it is stable which verified the Theorem 5.

The effect of the immune response rate α is plotted in Figure 2. We observe that in the absence of the drug, the CTL count and ACE2 increase with increasing value of α . The steady-state value of infected cell I^* and virus V^* decreases significantly as α increases.

Due to the impulsive nature of the drugs, there are no equilibria of the system; i.e., population does not reach

towards the equilibrium point, rather approach a periodic orbit. Hence, we evaluate equilibrium-like periodic orbits. There are two periodic orbits of system (3), namely, the disease-free periodic orbit and endemic periodic orbit. Here, our aim is to find the stability of the disease-free periodic orbit.

Figure 3 compares the system without and with impulse drug effect. In the absence of the drug, we observe that the CTL count approaches a stable equilibrium. Under regular drug dosing, the CTL count oscillates in an impulsive periodic orbit. Assuming perfect adherence, if the drug is sufficiently strong, both infected cell and virus population approach towards extinction. In this case, the total number




FIGURE 3: Numerical solution of the model system with and without the drug dose is shown taking parameters as in Figure 1. In this figure, $\tau = 2$ and $\omega = 50$.

of uninfected cells reaches its maximum level which implies that the system approaches towards its infection-free state (Theorem 11).

If we take sufficiently large impulsive interval $\tau = 5$ days (keeping rate $\omega = 50$ fixed, as in Figure 3) or lower dosage effect $\omega = 20$ (keeping interval $\tau = 2$ fixed, as in Figure 3), in both the cases, infection remains present in the system. Thus, the proper dosage of drug and optimal dosing interval are important for infection management.

6. Conclusion

In this article, the role of the immunostimulant drug (mainly pidotimod) during interactions between SARS-CoV-2 spike protein and epithelial cell receptor ACE2 in COVID-19 infection has been studied as a possible drug dosing policy. To reactivate the CTL responses during the acute infection period, immune activator drugs are delivered to the host system in an impulsive mode.




FIGURE 4: Numerical solution of the model system for different rates of drug dosing and different intervals of impulses.

When the immunostimulant drug is administered, the best possible CTL responses can act against the infected or virus-producing cells to neutralize infection. This particular situation can keep the infected cell population at a very low level. In the proposed mathematical model, we have analyzed the optimal dosing regimen for which infection can be controlled.

From this study, it has been observed that when the basic reproduction ratio lies below one, we expect the system to

attain its disease-free state. However, the system switches from the disease-free state to the CTL-free equilibrium state when $1 < R_0 < 2.957$. If $R_0 > 2.957$, the CTL-free equilibrium moves to an endemic state (Figure 1).

Here, we have explored the immunostimulant drug dynamics by the help of impulsive differential equations. With the help of impulsive differential equations, we have studied how the effect of the maximal acceptable optimal

dosage can be found more precisely. The impulsive system shows that the proper dosage and dosing intervals are important for the eradication of the infected cells and virus population which results in the control of the pandemic (Figure 3).

It has also been observed that the length of the dosing interval and the drug dose play a very decisive role to control and eradicate the infection. The most interesting prediction of this model is that effective therapy can often be achieved, even for low adherence, if the dosing regimen is adjusted appropriately (Figure 4). Also, if the treatment regimen is not adjusted properly, the therapy is not effective at all. This approach might also be applicable to a combination of antiviral therapy.

Future extension work of the combination of drug therapy should also include more realistic patterns of nonadherence (random drug holidays, imperfect timing of successive doses) and more accurate intracellular pharmacokinetics which leads towards better estimates of drug dosage and drug dosing intervals.

We end the paper with the quotation: “*This outbreak is a test of political, financial and scientific solidarity for the world to fight a common enemy that does not respect borders..., what matters now is stopping the outbreak and saving lives,*” by Dr. Tedros, Director General, WHO [31].

Appendix

Analysis of the System without the Drug

$$A_1 = -(a_{11} + a_{22} + a_{33} + a_{44} + a_{55}),$$

$$A_2 = a_{11}(a_{22} + a_{33}) + a_{23}a_{32} + a_{22}a_{33} - a_{14}a_{41} \\ + (a_{11} + a_{22} + a_{33})a_{44} - a_{25}a_{52} + (a_{11} + a_{22} + a_{33} + a_{44})a_{55},$$

$$A_3 = a_{32}(a_{11}a_{23} - a_{13}a_{21} - a_{24}a_{43}) - a_{11}a_{22}(a_{44} + a_{33}) \\ + a_{14}a_{33}a_{41} + a_{44}(a_{23}a_{32} - a_{11}a_{33} - a_{22}a_{33}) \\ + a_{25}a_{52}(a_{33} + a_{44} + a_{11}) - a_{11}a_{55}(a_{22} + a_{33}) \\ + a_{23}a_{32}a_{55} - a_{22}a_{33}a_{55} - a_{44}a_{55} \\ \cdot (a_{11} + a_{14}a_{41}a_{55} + a_{22} + a_{33}) + a_{14}a_{22}a_{41},$$

$$A_4 = a_{32}a_{41}(a_{23}a_{14} - a_{13}a_{24}) - a_{22}a_{33}(a_{14}a_{41} - a_{44}a_{55}) \quad (A.1) \\ - a_{14}a_{21}a_{32}a_{43} + a_{13}a_{21}a_{32}a_{44} - a_{11}(a_{23}a_{32}a_{44} + a_{25}a_{33}a_{52}) \\ + a_{52}(a_{14}a_{25}a_{41} - a_{11}a_{25}a_{44} - a_{25}a_{33}a_{44}) + a_{13}a_{21}a_{32}a_{55} \\ - a_{11}a_{55}(a_{23}a_{32} - a_{22}a_{33}) - a_{41}a_{55}(a_{14}a_{22} + a_{14}a_{33}) \\ + a_{55}(a_{24}a_{32}a_{43} + a_{11}a_{22}a_{44} - a_{23}a_{32}a_{44}) \\ + a_{11}a_{33}(a_{22}a_{44} + a_{44}a_{55}) + a_{11}a_{24}a_{32}a_{43},$$

$$A_5 = a_{25}a_{33}(a_{11}a_{44}a_{52} - a_{14}a_{41}a_{52}) + (a_{14}a_{21}a_{32} - a_{11}a_{24}a_{32})a_{43}a_{55} \\ + a_{41}a_{55}(a_{13}a_{24}a_{32} - a_{14}a_{23}a_{32} + a_{14}a_{22}a_{33}) \\ + a_{44}a_{55}(a_{11}a_{23}a_{32} - a_{13}a_{21}a_{32} - a_{11}a_{22}a_{33}).$$

$$B_1 = -(b_{11} + b_{22} + b_{33} + b_{44}),$$

$$B_2 = b_{11}b_{22} - b_{23}b_{32} + b_{33}(b_{11} + b_{22}) - b_{14}b_{41} + b_{44}(b_{11} + b_{22} + b_{33}),$$

$$B_3 = b_{32}(b_{11}b_{23} - b_{13}b_{21}) - b_{22}(b_{11}b_{33} - b_{14}b_{41}) \quad (A.2) \\ + b_{14}b_{33}b_{41} - b_{24}b_{32}b_{43} + (b_{23}b_{32} - b_{11}b_{22})b_{44} - b_{33}b_{44}(b_{11} + b_{22}),$$

$$B_4 = b_{14}b_{41}(b_{23}b_{32} - b_{22}b_{33}) - b_{13}b_{24}b_{32}b_{41} - b_{14}b_{21}b_{32}b_{43} \\ + b_{32}(b_{11}b_{24}b_{43} + b_{13}b_{21}b_{44}) - b_{44}b_{11}(b_{23}b_{32} - b_{22}b_{33}).$$

Data Availability

The data used for supporting the findings are included within the article.

Conflicts of Interest

The authors declare that there is no conflict of interest.

Authors' Contributions

Both authors contributed equally to this work.

References

- [1] P. Zhou, X. L. Yang, X. G. Wang et al., “A pneumonia outbreak associated with a new coronavirus of probable bat origin,” *Nature*, vol. 579, no. 7798, pp. 270–273, 2020.
- [2] P. R. Hsueh, L. M. Huang, P. J. Chen, C. L. Kao, and P. C. Yang, “Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus,” *Clinical Microbiology and Infection*, vol. 10, no. 12, pp. 1062–1066, 2004.
- [3] N. Zhu, D. Zhang, W. Wang et al., “A novel coronavirus from patients with pneumonia in China, 2019,” *The New England Journal of Medicine*, vol. 382, no. 8, pp. 727–733, 2020.
- [4] World Health Organization, “*WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020*,” Switzerland, Geneva, 2020.
- [5] L. Zou, F. Ruan, M. Huang et al., “SARS-CoV-2 viral load in upper respiratory specimens of infected patients,” *New England Journal of Medicine*, vol. 382, no. 12, pp. 1177–1179, 2020.
- [6] World Health Organization, “*Considerations for quarantine of individuals in the context of containment for coronavirus disease (COVID-19): interim guidance*,” 2020, 29 February 2020.
- [7] Y. Wan, J. Shang, R. Graham, R. S. Baric, and F. Li, “Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus,” *Journal of Virology*, vol. 94, no. 7, 2020.
- [8] H.-L. J. Oh, S. K.-E. Gan, A. Bertoletti, and Y.-J. Tan, “Understanding the T cell immune response in SARS coronavirus infection,” *Emerging Microbes & Infections*, vol. 1, no. 1, pp. 1–6, 2012.
- [9] G. Li and E. De Clercq, “Therapeutic options for the 2019 novel coronavirus (2019-nCoV),” *Nature Reviews Drug Discovery*, vol. 19, no. 3, pp. 149–150, 2020.

- [10] H. A. Rothan and S. N. Byrareddy, "The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak," *Journal of Autoimmunity*, vol. 109, 2020.
- [11] M. Zheng, Y. Gao, G. Wang et al., "Functional exhaustion of antiviral lymphocytes in COVID-19 patients," *Cellular & Molecular Immunology*, vol. 17, no. 5, pp. 533–535, 2020.
- [12] S. Qureshi and A. Yusuf, "Fractional derivatives applied to MSEIR problems: comparative study with real world data," *The European Physical Journal Plus*, vol. 134, no. 4, p. 171, 2019.
- [13] S. Qureshi and A. Yusuf, "Transmission dynamics of varicella zoster virus modeled by classical and novel fractional operators using real statistical data," *Physica A: Statistical Mechanics and its Applications*, vol. 534, p. 122149, 2019.
- [14] S. Tang, W. Ma, and P. Bai, "A novel dynamic model describing the spread of the MERS-CoV and the expression of dipeptidyl peptidase 4," *Computational and mathematical methods in medicine*, vol. 2017, Article ID 5285810, 6 pages, 2017.
- [15] M. A. Nowak and R. M. May, *Virus Dynamics: Mathematics Principles of Immunology and Virology*, Oxford University Press, London, UK, 2000.
- [16] A. S. Perelson and P. W. Nelson, "Mathematical analysis of HIV-1 dynamics in vivo," *SIAM Review*, vol. 41, no. 1, pp. 3–44, 1999.
- [17] A. N. Chatterjee, S. Saha, and P. K. Roy, "Human immunodeficiency virus/acquired immune deficiency syndrome: using drug from mathematical perspective," *World Journal of Virology*, vol. 4, no. 4, pp. 356–364, 2015.
- [18] P. K. Roy, A. N. Chatterjee, D. Greenhalgh, and Q. J. A. Khan, "Long term dynamics in a mathematical model of HIV-1 infection with delay in different variants of the basic drug therapy model," *Nonlinear Analysis: Real World Applications*, vol. 14, no. 3, pp. 1621–1633, 2013.
- [19] F. Puggioni, M. Alves-Correia, M. F. Mohamed et al., "Immunostimulants in respiratory diseases: focus on pidotimod," *Multidisciplinary Respiratory Medicine*, vol. 14, no. 1, pp. 1–10, 2019.
- [20] R. E. Miron and R. J. Smith, "Modelling imperfect adherence to HIV induction therapy," *BMC Infectious Diseases*, vol. 10, no. 1, p. 6, 2010.
- [21] J. Lou and R. J. Smith, "Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide," *Journal of Theoretical Biology*, vol. 268, no. 1, pp. 1–13, 2011.
- [22] R. J. Smith and B. D. Aggarwala, "Can the viral reservoir of latently infected CD4(+) T cells be eradicated with antiretroviral HIV drugs?," *Journal of Mathematical Biology*, vol. 59, no. 5, pp. 697–715, 2009.
- [23] R. J. Smith, "Explicitly accounting for antiretroviral drug uptake in theoretical HIV models predicts long-term failure of protease-only therapy," *Journal of Theoretical Biology*, vol. 251, no. 2, pp. 227–237, 2008.
- [24] R. J. Smith and L. M. Wahl, "Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects," *Bulletin of Mathematical Biology*, vol. 67, no. 4, pp. 783–813, 2005.
- [25] J. LOU, L. CHEN, and T. RUGGERI, "An impulsive differential model on post exposure prophylaxis to HIV-1 exposed individual," *Journal of Biological Systems*, vol. 17, no. 4, pp. 659–683, 2011.
- [26] P. K. Roy, A. N. Chatterjee, and X. Z. Li, "The effect of vaccination to dendritic cell and immune cell interaction in HIV disease progression," *International Journal of Biomathematics*, vol. 9, no. 1, 2015.
- [27] E. Qing and T. Gallagher, "SARS coronavirus redux," *Trends in Immunology*, vol. 41, no. 4, pp. 271–273, 2020.
- [28] H. Yu, S. Zhong, and R. P. Agarwal, "Mathematics analysis and chaos in an ecological model with an impulsive control strategy," *Communications in Nonlinear Science and Numerical Simulation*, vol. 16, no. 2, pp. 776–786, 2011.
- [29] V. Lakshmikantham, D. D. Bainov, and P. S. Simeonov, "Theory of impulsive differential equations," in *Series in Modern Applied Mathematics*, vol. 6, World Scientific Publishing, 1989.
- [30] C. Wu, Y. Liu, Y. Yang et al., "Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods," *Acta Pharmaceutica Sinica B*, vol. 10, no. 5, pp. 766–788, 2020.
- [31] World Health Organization, "Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance," World Health Organization, 2020.
- [32] H. Xu, L. Zhong, J. Deng et al., "High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa," *International Journal of Oral Science*, vol. 12, no. 1, p. 8, 2020.
- [33] J. Chen, C. Hu, L. Chen et al., "Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment," *Engineering*, 2020.